Amgen has shed light on its phase 2 lupus win, revealing that its monoclonal antibody daxdilimab was tied to a 6-point reduction in disease severity at the lower dose.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
